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Abstract: Background: Although photodynamic therapy (PDT) has become the standard treatment
for central serous chorioretinopathy (CSC), its mechanism of action remains unclear. It is assumed that
PDT induces short-term choriocapillaris (CC) occlusion and long-term choroidal vascular remodeling.
In this paper, we describe the short-term CC changes induced by Half-Dose PDT (HD-PDT)
in chronic CSC using optical coherence tomography-angiography (OCTA). Methods: This is a
prospective interventional case series. Chronic CSC eyes underwent Spectral-Domain OCT,
Fundus Autofluorescence, FA, ICGA (Heidelberg Spectralis, Heidelberg, Germany) and OCTA
(RTVue XR Avanti with AngioVue; Optovue Inc., Fremont, CA, USA) before HD-PDT, with follow-up
after one hour, one week, and one month. Vascular changes after PDT were analyzed within the
CC layer. The CC vessel density was defined as the percentage of an area occupied by flow pixels,
using Image J software to obtain measurements by applying a grey level threshold. All pixels with
a grey level above the threshold were considered as indicators of blood flow. Results: 20 eyes of
19 patients were included. At baseline the mean CC vessel density was 94.87 ± 2.32%. It significantly
differed from the density at 1 week and 1 month (92.79 ± 3.16% and 95.55 ± 2.05%, p < 0.001,
respectively), but not with values at 1 h (94.8 ± 2.28%, p = 0.516). Conclusions: CC vessel density was
significantly reduced at 1 week as compared with baseline, suggesting a possible short-term effect
of PDT on CC perfusion. After 1 month however, the CC vessel density was even higher than the
baseline, probably due to a CC recovery. OCTA seems to be useful in the visualization of CC vessels
and in confirming the mechanism of action of PDT treatment in eyes with chronic CSC.
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1. Introduction
Central serous chorioretinopathy (CSC) is a posterior segment disease that represents a common
cause of vision threat in the middle-aged population. It is characterized by the presence of a
localized and limited accumulation of fluid under the neurosensory retina through a defect of the
retinal pigment epithelium (RPE) [1,2]. CSC often resolves spontaneously but sometimes recurs or
becomes chronic [1,3].
The distinction between acute and chronic forms relies on the presence of persistent serous retinal
detachment, extended RPE and photoreceptor atrophic changes correlated with a progressive visual
loss over a period of 3–6 months [4–6]. This arbitrary demarcation has therapeutic implications as it
usually determines the timing for intervention.
Classically, treatment is justified in case of persistent macular neuroretinal detachment or posterior
cystoid retinal degeneration, history of multiple recurrences, history of CSC in the fellow eye with
poor visual outcome, reduced visual acuity and rapid recovery required [7].
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Up to now, there is no recognized standard therapy for chronic CSC which would allow for the
prevention of progressive pigment epithelium and photoreceptor damage leading to irreversible visual
impairment [8]. Although there are no phase 3 randomized clinical trials, photodynamic therapy (PDT)
is now considered the treatment of choice for chronic CSC.
The efficacy of PDT—in particular half-dose or half-fluence PDT in eyes affected by CSC—has been
widely studied and documented [9–11]. However, the mechanisms of the actions of PDT in chronic CSC
remain unclear. Chan et al., speculated that PDT induces short-term choriocapillaris (CC) occlusion
and long-term choroidal vascular remodeling [12]. These changes result in caliber normalization of
dilated, congested, choroidal vessels and subsequent reduction of vascular hyperpermeability and
leakage. Imaging techniques and histological findings have demonstrated the effects of vascular
occlusion at the CC level due to PDT, even a few days after the treatment [13].
Recently, new imaging technologies have been developed and allow for new insights in the
visualization of normal and pathologic vascularization. In particular, optical coherence tomography
angiography (OCTA) is now able to individually visualize the superficial and deep retinal plexi, analyze
the outer retina together and the CC layer without the need for dye injection [14]. OCTA findings in
chronic CSC have been previously reported and have demonstrated that OCTA can detect dilated CC
vessels and even choroidal neovascularization (CNV), not visible with other imaging techniques [15,16].
The aim of our study is to describe the short-term CC changes induced by Half-Dose PDT
(HD-PDT) in the treatment of chronic CSC using OCTA.
2. Results
Using the Shapiro-Wilk test, all data sets resulted normally distributed (p > 0.05) [17].
2.1. Baseline Characteristics
Twenty eyes of 19 patients received half-dose PDT. Demographic data are shown in Table 1.
Table 1. Baseline demographic characteristics.
Characteristic Value± SD
Mean Age ± Standard Deviation (Years) 51.8 ± 8.01
Sex (Male/Female) 18/1
Mean duration of CSC ± Standard Deviation (Years) 3.34 ± 1.40
Patients with bilateral CSC (n) 3
2.2. Visual Acuity
At baseline the mean best corrected visual acuity (BCVA) was 0.34 ± 0.23 LogMAR
(Snellen equivalent: range 20/125–20/20; median 20/40). At one week and 1 month, BCVA was
0.31± 0.20 LogMAR (Snellen equivalent: range 20/100–20/25; median 20/40) and 0.26± 0.19 LogMAR
(Snellen equivalent: range 20/100–20/25; median 20/40) respectively. There was no significant
difference between BCVA at baseline and 1 week (p = 0.29). BCVA at the 1 month follow up visit was
significantly different from the baseline (p = 0.02) (Table 2).
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Table 2. Mean Best Corrected Visual Acuity (BCVA), Central Foveal Thickness (CFT), Choroidal
Thickness (CHT) and Choriocapillary Vessel Density (CCVD) in 20 eyes with Chronic Central Serous
Chorioretinopathy treated with half-dose photodynamic therapy. SD: standard deviation; 1 h: 1 hour;
1 w: 1 week; 1 m: 1 month.
Characteristic Baseline 1 h p (Baselinevs. 1 h) 1 w
p (Baseline
vs. 1 w) 1 m
p (Baseline
vs. 1 m)
BCVA ± SD (LogMAR) 0.34 ± 0.23 N/A N/A 0.31 ± 0.20 0.287 0.26 ± 0.19 0.016
CFT ± SD (µm) 348.3 ± 144.42 332.7 ± 112.87 0.107 284.4 ± 67.08 0.01 249.75 ± 42.66 0.005
CHT ± SD (µm) 395.8 ± 89.61 397.1 ± 93.98 0.878 381.9 ± 93.88 0.134 364.55 ± 108.5 0.009
CCVD ± SD (%) 94.87 ± 2.32 94.8 ± 2.28 0.516 92.79 ± 3.16 <0.001 95.55 ± 2.05 <0.001
2.3. PDT
Complete resolution of subretinal fluid was observed in 12 eyes (60%) after 1 week and in 16 eyes
(80%) after 1 month. Two cases achieved clinical healing at 3 months after treatment, while the two
remaining eyes presented persistence of subretinal fluid and needed a second PDT treatment.
2.4. OCT
At baseline the mean central foveal thickness (CFT) was 348.3 ± 144.42 µm. At one hour, one week
and one month it was 332.7 ± 112.87; 284.4 ± 67.08 and 249.75 ± 42.66 µm respectively. The CFT at
baseline was significantly different from CFT at 1 week (p = 0.01) and 1 month (p = 0.005) but not at 1 h
(p = 0.107) (Table 2).
The mean choroidal thickness (CHT) was 395.8 ± 89.61 µm. At one hour, one week and one
month it was 397.1 ± 93.98; 381.9 ± 93.88 and 364.55 ± 108.5 µm respectively. The CHT at baseline
was significantly different from CHT at one month (p = 0.009) but not at 1 h (p = 0.878) and 1 week
(p = 0.134) (Table 2).
The mean CHT of fellow eyes was 284 ± 157.8 µm. It was statistically thinner than the affected
eyes at any visit (p < 0.001).
2.5. OCTA
2.5.1. Repeatability Assessment
Two different operators (M.N. and C.L.) performed all CCVD measurements. No significant
difference was found between the two datasets (p = 0.114) and the intraclass correlation coefficient
(ICC) was 0.982 (95% confidence interval [CI]: 0.972–0.988).
Mean values between the two measurements were used for further analysis.
2.5.2. Affected Eyes
At baseline the mean CC vessel density was 94.87 ± 2.32%. It significantly differed from the
density at 1 week (92.79 ± 3.16%, p < 0.001) and at 1 month (95.55 ± 2.05%, p < 0.001), but not with
values at 1 h (94.8 ± 2.28%, p = 0.516) (Table 2).
CC vessel density was significantly reduced at 1 week as compared with baseline, suggesting a
possible short-term effect of PDT on CC perfusion. At 1 month, however, CC vessel density was even
higher than baseline, probably due to a CC recovery (Figure 1).
No significant correlation was found between CFT and CCVD measurements (Spearman
coefficient: −0.183, p = 0.103).
2.5.3. Comparison with Fellow Eyes
For the analysis of fellow eyes, we excluded 3 patients because of bilateral CSC. We evaluated
16 healthy eyes from 16 patients. The mean CC vessel density for fellow eyes was 98.31 ± 0.98%
Int. J. Mol. Sci. 2017, 18, 2468 4 of 10
and it differed significantly from data of the corresponding pathologic eyes at all stages of
follow-up (p < 0.001).
This finding may be explained by a CC compression by bigger choroidal vessels occurring in
affected eyes as compared with their healthy fellow eyes.Int. J. Mol. Sci. 2017, 18, 2468  4 of 10 
 
 
Figure 1. (A,B) Fluorescein Angiography (FA) and Indocyanine Green Angiography (ICGA) of an eye 
affected by chronic central serous choriorethinopathy (CSC); (C–I) Choriocapillaris (CC) vessel 
density evaluation before and after photodynamic (PDT) treatment in eyes affected by chronic CSC; 
(C) “Outer retina” Optical Coherence Tomography Angiography (OCTA) slab between 70 μm below 
inner plexiform layer and 30 μm below the RPE reference; (F–I) 30 μm slab OCTA CC image with the 
analyzed circle area (1 mm diameter) at baseline (F); 1 h (G); 1 week (H) and 1 month (I) after PDT; 
(D) Histogram analysis with the exclusion of all pixels having grey values below the individual noise 
level seen in (C); (E) OCTA B-scan of the baseline. 
3. Discussion 
Chronic CSC is a cause of progressive visual loss due to the persistence of the neuroepithelium 
serous detachment [18]. Even though there is no approved therapy for such a disease, PDT treatment 
with verteporfin showed good efficacy in resolving the subretinal fluid, even after long term follow-
up [9,19]. 
In this study we demonstrated the short term PDT effects at the level of the choroid and the CC 
vessels in particular. 
In the present series, significant CFT and CHT reduction together with BCVA improvement 
were observed starting one month after PDT, as expected. In our study the resolution of subretinal 
fluid at one month was observed in 16 eyes (80%). Clinical healing was achieved three months after 
the treatment in two cases, while the two remaining eyes showed persistent subretinal fluid requiring 
a second PDT treatment. Our results are similar to those of previous studies using half-dose PDT. In 
particular, Chan et al., showed a complete resolution of subretinal fluid in 79.5% at one month and 
94.9% at 12 months, with only one recurrence [20]. More recently, Nicolò et al., reported similar 
results, with a success rate of 86.2% at one month and 100% at 12 months [11]. 
In this study we measured the CC vessel density in eyes with chronic CSC. We found a reduction 
of the CC vessel density one week after PDT treatment, while one month later it improved compared 
to the baseline. These observations support the hypothesis proposed to explain the mechanism of the 
actions of PDT treatment in CSC. In fact, PDT treatment seems to be able to induce some narrowing 
and remodeling of the choroidal vessels, thereby reducing choroidal exudation and, consequently, 
subretinal fluid [21]. 
OCTA is a new non-invasive imaging technique with interesting clinical applications and which 
is easy to perform. Recently, Xu et al. [22] have provided a qualitative short-term evaluation of the 
CC in patients with chronic CSC who underwent half-dose PDT. In their study CC changes after PDT 
support the hypothesis of short-term CC hypoperfusion after PDT, in line with our findings. Other 
authors described similar observations in a Japanese cohort [23]. 
Figure 1. (A,B) Fluorescein Angiography (FA) and Indocyanine Green Angiography (ICGA) of an
eye affected by chronic central serous choriorethinopathy (CSC); (C–I) Choriocapillaris (CC) vessel
density evaluation before and after photodynamic (PDT) treatment in eyes affected by chronic CSC;
(C) “Outer retina” Optical Coherence Tomography Angiography (OCTA) slab between 70 µm below
inner plexiform layer and 30 µm below the RPE reference; (F–I) 30 µm slab OCTA CC image with the
analyzed circle area (1 mm diameter) at baseline (F); 1 h (G); 1 week (H) and 1 month (I) after PDT;
(D) Histogram analysis with the exclusion of a l pixels having grey values below the individual noise
level seen in (C); (E) OCTA B-scan of the baseline.
3. Discussion
Chronic CSC is a cause of progressive visual loss due to the persistence of the neuroepithelium
serous detachment [18]. Even though there is no approved therapy for such a disease, PDT treatment
with verteporfin showed good efficacy in resolving the subretinal fluid, even after long term
follow-up [9,19].
In this study w demonstrated the short term PDT effects at the level of the choroid and the CC
vessels in particular.
In the present series, significant CFT and CHT reduction together with BCVA improvement were
observed starting one month after PDT, as expected. In our study the resolution of subretinal fluid
at one month was observed in 16 eyes (80%). Clinical healing was achieved three months after the
treatment in two cases, while the two remaining eyes showed persistent subretinal fluid requiring
a second PDT treatment. Our results are similar to those of previous studies using half-dose PDT.
In particular, Chan et al., showed a complete resolution of subretinal fluid in 79.5% at one month and
94.9% at 12 months, with only one recurrence [20]. More recently, Nicolò et al., re orte si ilar results,
with a succes rat of 86.2% at one month and 100% at 12 months [11].
In this study we measured the CC vessel densi y i ey s with chronic CSC. We fou d a reduction
of the CC vessel density one week after PDT treatment, while one month later it improved compared
to the baseline. These observations support the hypothesis proposed to explain the mechanism of the
actions of PDT treatment in CSC. In fact, PDT treatment seems to be able to induce some narrowing
and remodeling of the choroidal vessels, thereby reducing choroidal exudation and, consequently,
subretinal fluid [21].
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OCTA is a new non-invasive imaging technique with interesting clinical applications and which
is easy to perform. Recently, Xu et al. [22] have provided a qualitative short-term evaluation of the
CC in patients with chronic CSC who underwent half-dose PDT. In their study CC changes after PDT
support the hypothesis of short-term CC hypoperfusion after PDT, in line with our findings. Other
authors described similar observations in a Japanese cohort [23].
In CSC-fellow eyes, the CC vessel density was similar to that found by Alten et al.,
in an age-matched group of normal eyes [24]. The CC vessel density found in treated eyes was
somewhat inferior compared to fellow eyes: Even though the choroid is thicker, a CC compression
from bigger choroidal vessels may have occurred in the affected eyes. Costanzo et al., studying
the OCTA features in patients affected by CSC, reported a rarefaction of the CC plexus and the
presence of “dark areas”, probably due to focal atrophy secondary to compression by the enlarged
choroidal vessels [25,26].
The increase in “dark areas” observed one week after PDT may be related to the reabsorption
of subretinal fluid, allowing a better visualization of the CC with higher contrast and less signal
fragmentation. Nevertheless, the reduction of subretinal fluid (SRF) and CFT observed one week and
one month after the treatment were similar, while CC vessel densities were rather different. We can
therefore postulate that artifacts due to the possible SRF masking effect would have had similar effects
at these timelines, suggesting that CC vessel density changes may have occurred between seven and
30 days after PDT. Furthermore, no correlation was found between CFT and CCVD. The increase of
dark areas might even be related to the occlusion of the CC vessels, as an effect of PDT treatment.
This theory has been proven by Schlötzer-Schrehardt et al., who demonstrated a selective damage on
CC endothelial cells [12,27] with a preservation of bigger choroidal vessels. The damage induced by
PDT may be responsible for the significant decrease in CC vessel density observed one week after the
treatment. As the effect of PDT involves not only the targeted points of vascular focal loss, but even
the surrounding areas, large dark areas are clearly visible in many OCTA scans.
It is possible that both focal atrophy due to compression by enlarged choroidal vessels and
CC occlusion due to PDT may concur in producing these “dark areas” in CSC patients but further
investigations are needed in order to clarify this point.
One month after the treatment, a significant increase in CC vessel density was observed,
with values even higher than at baseline. This finding could be related to a process of recovery
at the CC level after PDT. The effects of PDT on the choroid resulted in an increased expression of
vascular endothelial growth factor (VEGF) and its receptors (VEGF-R) in the treated area, probably
due to hypoxia and endothelial cells death [28]. Husain et al., demonstrated CC reperfusion in the
normal choroid occurring within seven weeks from treatment, while Schlötzer-Schrehardt found CC
recanalization as early as one week [29]. Moreover, CC vessel density recovery could be related to a
decreased compression exerted by larger choroidal vessels.
The present study has several limitations and some considerations are dutiful.
Due to the present lack of standardization in CC analysis, vessel density results should be
interpreted with caution and are not comparable to those reported in other studies using different
thresholding and calculation methods [30,31].
3 × 3 mm scan dimension was preferred to the 6 × 6 mm because of its higher resolution,
especially for CC evaluation and processing. Moreover, the evaluated area was small and was the
same for every patient at all follow-up. Image artifacts were reported more often when using 3 × 3 mm
scan, and these artifacts were also more frequent in elderly people with poor fixation [24].
In this study the standard 30 µm CC slab was used to evaluate CC vessel density with OCTA.
Even if a manual segmentation was performed in cases of unsatisfying automated procedure, a different
slab could have been chosen. The 30 µm slab at the CC level includes even parts of the larger
choroidal vessels: A “tailored” slab could have brought to different and maybe more accurate
results. However, Alten et al., studying reticular pseudodrusen (RPD) features using the OCTA,
found no significant differences between 10 and 30 µm slabs within the CC in affected patients [24].
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Due to different CC and choroid conditions in CSC and RPD, these considerations are only hypothesis
and further research is needed.
Patients with pigment epithelium detachment (PED) or posterior cystoid retinal degeneration
were excluded from the study. As the aim of the article was to evaluate the CC structural changes
after HD-PDT in patients with chronic CSC, patients with PED were excluded due to the segmentation
difficulties deriving from the CC displacement observed in PED, as previously reported [32].
Cystoid retinal degeneration in CSC is a recognized complication of chronic CSC and is associated
with a severe reduction of visual acuity as a result of long-term disease [33]. In this condition it could
have been impossible to obtain good quality images from those patients, hence the prior exclusion
from the study.
4. Materials and Methods
This prospective interventional case series included 20 eyes of 19 consecutive patients (18 males,
mean age 51.8 ± 8.01 years, range 33–62 years) affected by chronic CSC that underwent half-dose PDT
with verteporfin at our Eye Clinic in Turin, Italy.
The study was approved by the Institutional Review Board of the University of Turin (CS/723,
14 March 2016, Comitato Etico Interaziendale A.O.U. Città della Salute e della Scienza di Torino—
A.O. Ordine Mauriziano di Torino—A.S.L. TO 1). Informed consent for PDT and for clinical research
was obtained from all patients and the study was conducted in accordance with the provisions stated
in the Declaration of Helsinki.
Chronic CSC was defined as persistence of subretinal fluid involving the fovea for six months
or more.
Inclusion criteria of the study were:
1. Snellen BCVA of 20/200 or better
2. Presence of active leakage on fluorescein angiography (FA) and choroidal vascular
hyperpermeability on indocyanine green angiography (ICGA)
3. Absence of CNV evidence on OCTA, FA and ICGA
4. Absence of PED or posterior cystoid retinal degeneration
5. Absence of any previous treatment
6. Absence of any other chorioretinal disease
7. Absence of media opacities
BCVA was measured at baseline and after one month visit using the Early Treatment Diabetic
Retinopathy Study (ETDRS) charts by certified examiners (M.N. and C.L.). Spectral Domain OCT
(SD-OCT), Fundus Autofluorescence (FAF), FA, ICGA (Heidelberg Spectralis, Heidelberg, Germany)
and OCTA (RTVue XR Avanti with AngioVue; Optovue Inc., Fremont, CA, USA) were performed by
certified examiners after pupillary dilatation (C.M.E., C.A.).
Cross-line SD-OCT scan confirmed the presence of macular serous detachment. CFT was
measured using the Retina Map pattern and the provided ETDRS grid in the central millimeter.
Each section was obtained using eye tracking ART (Automatic Real-Time) and 100 scans were averaged
to improve the signal-to-noise ratio. Enhanced depth imaging (EDI) technique was used to calculate
CHT using the attached measuring software. Central choroidal thickness was measured under the
center of the fovea as previously described [34]. The subfoveal CHT was measured from the outer
surface of the line formed by the RPE to the inner surface of the observed sclera and calculated as the
mean value between vertical and horizontal line scans.
The baseline visit was performed within one week before the PDT treatment. All patients
underwent a complete ophthalmic examination including: BCVA, anterior segment examination,
intraocular pressure measurement with Goldmann applanation tonometry and dilated fundus
biomicroscopy. FAF, FA and ICGA were also performed. SD-OCT and OCTA examination were
performed right before the PDT treatment, one hour after, and after one week and one month visit.
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Baseline examinations were performed even in fellow eyes. If no signs of CSC or any other ocular
pathology was detected in fellow eyes, they were used to make comparisons in terms of CHT and CC
vessel density.
Patients satisfying the inclusion criteria, underwent ICGA guided HD-PDT (3 mg/m2)
as previously described [35]. Briefly, verteporfin (Visudyne; Novartis AG, Basel, Switzerland)
was infused for 10 min followed by 83 s of laser treatment at 693 nm (total energy 50 J/cm2)
delivered 15 min after the beginning of the infusion. HD-PDT was targeted to the areas of choroidal
hyper-permeability visible on ICGA supposed to cause the serous detachment.
4.1. OCT-Angiography
Optovue RTVue XR Avanti Spectral-Domain (SD) OCT with AngioVue was used to obtain
amplitude-decorrelated angiography images. The instrument has an A-scan rate of 70,000 scans per
second, a light source centered at 840 nm and a bandwidth of 45 nm. Each OCTA volume contains
304 × 304 A-scans and is acquired over three s. Two consecutive orthogonal OCTA volumes are
acquired to perform a motion correction which automatically minimize the motion artifacts due to
microsaccades (i.e., motion correction technology [MCT]). Using the Split-spectrum method (SSADA),
measurement noise was reduced by splitting the signal into eleven wavelengths.
An algorithm of the software (Version 2015.100.0.35; Optovue Inc., Fremont, CA, USA) analyses
and calculates each pixel location and combines horizontal and vertical scans averaging the
decorrelation values to create a 3-dimensional angiographic data cube. The modifications in reflectivity
are directly linked to blood flow. The software automatically segments the tissue in four layers:
The superficial layer (from the inner limiting membrane to the inner nuclear layer), the deep layer
(from the inner nuclear layer to the outer plexiform layer), the outer retina layer (from the outer
plexiform layer to the retinal pigment epithelium) and the CC layer.
Vascular changes after PDT treatment were analyzed within the CC layer. The visualization of the
CC layer was obtained using the standard setting of the instrument which gives a 30 µm-slab between
30 and 60 µm below the inner RPE reference. As slabs were automatically-generated, all segmentations
were checked and eventually manually adjusted for accuracy.
3 × 3 mm OCTA acquisitions were centered in the leakage area on FA or hyperpermeable spot on
ICGA images before PDT treatment; the follow-up mode was then used for the following examinations.
Images showing an inadequate signal (signal strength index < 60) or evidence of signal blockage on
the En-Face scans of the CC were excluded.
Using the software Image J (National Institutes of Health; http://imagej.nih.gov/ij/)
a 1-mm-diameter circle was traced in the center of the 3 × 3 mm OCT angiograms. The appropriate
position of the circle was verified using the angiographic images and the vascular plexi of the inner
retina imaged with OCTA as references.
Mean gray levels of the four layers of each image were assessed using Image J software.
As previously described [24], the CC vessel density was defined as the percentage area occupied
by flow pixels obtained by applying a grey level threshold. The grey level threshold was used to
reduce the noise and was defined as the average signal of the outer retinal layer, where normally no
vessels are found. All pixels with a grey level above the threshold were considered as indicators of
blood flow (Figure 2). In order to enhance reliability of our data we performed two consecutive OCTA
measurements in each eye by two different operators (MN and CL). Mean values were used for further
analysis. CC vessel density is expressed as percentage.
4.2. Data Analysis and Statistic
All data are presented as Mean ± Standard Deviation.
The Shapiro-Wilk test was used to verify the normal distribution of data [17].
Differences between data sets were evaluated with paired t-test.
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Repeatability between the two measurements from different operators was assessed evaluating
the ICC.
The Spearman coefficient was calculated to assess the correlation between CCVD and CFT.
p value < 0.05 was considered significant.Int. J. Mol. Sci. 2017, 18, 2468  8 of 10 
 
 
 
Figure 2. (A) The Indocyanine Green Angiography (ICGA, left) of an eye affected by chronic central 
serous choriorethinopathy (CSC) was used as reference to guide the photodynamic (PDT) treatment 
(black ellipsoid line); (E) The appropriate position of the circle on the optical coherence tomography 
angiography (OCTA) image was verified comparing the Fluorescein Angiography (FA; (A) right) 
image and the vascular plexus of the inner retina imaged with (OCTA) (B); (D) “Outer retina” OCTA 
slab between 70 μm below inner plexiform layer and 30 μm below the retinal pigment epithelium 
(RPE) reference was used to define the noise as the mean grey level of the picture (G). The mean grey 
level was used as a threshold to apply to the 30 μm slab OCTA choriocapillaris (CC) image (C), 
obtaining a binarized image where all pixels above the threshold (in black) were considered as 
indicators of blood flow (F). Using the previous superficial slab (E) as reference, the circle was placed 
on the binarized image in the same position (H). The area of the black pixels was automatically 
measured by ImageJ software. 
5. Conclusions 
In conclusion, the short-term analysis of the CC after PDT showed a decrease in vessel density 
one week after the treatment, probably due to capillary occlusion subsequent to treatment. The vessel 
density increase observed at one month may be due to CC recovery related to VEGF and VEGF-R 
overexpression at the treatment site. OCTA seems to be useful in the visualization of the CC vessels 
and in confirming the mechanism of action of PDT treatment in eyes with chronic CSC. 
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Figure 2. (A) The Indocyanine Green Angiography (ICGA, left) of an eye affected by chronic central
serous choriorethinopathy (CSC) was used as reference to guide the photodynamic (PDT) treatment
(black ellipsoid line); (E) The appropriate position of the circle on the optical coherence tomography
angiography (OCTA) image was verified comparing the Fl orescein Angiography (FA; (A) right)
image and the vascular plexus of the inner retina imaged with (OCTA) (B); (D) “Outer retina” OCTA
slab between 70 µm below inner plexiform layer and 30 µm below the retinal pigment epithelium
(RPE) reference was used to define the nois as the m an grey level of the picture (G). The mean
grey level was used as a threshold to apply to the 30 µm slab OCTA choriocapillaris (CC) image
(C), obtaining a binarized image wher all pixels above the threshold (in black) were consid red as
indicators of blood flow (F). Using the previous superficial sla (E) as reference, the circle was placed on
the binarized image in the s me position (H). The rea of t black pixels was utomatically measured
by ImageJ s tware.
5. Conclu ions
In conclusion, the short-term analysis of the CC after PDT showed a decrease in vessel density
one week after the treatment, probably due to capillary occlusion subsequent to treatment. The vessel
density increase observed at one month may be due to CC recovery related to VEGF and VEGF-R
overexpression at the treatment site. OCTA seems to be useful in the visualization of the CC vessels
and in confirming the mechanism of action of PDT treatment in eyes with chronic CSC.
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